Moderna Accelerates Its COVID-19 Vaccine Development Plan
One of the companies leading the race to develop a coronavirus vaccine is accelerating what had already been an ambitious timeline. On Thursday, Moderna (NASDAQ: MRNA) said mid-stage clinical trials for its SARS-CoV-2 vaccine candidate, mRNA-1273, would begin shortly, with late-stage studies slated to start in the early summer.
Previously, the company had expected mid-stage would begin some time before the end of June, and late-stage trials weren't expected to start until this fall.
Image source: Getty Images.
Source Fool.com
